Related Experiment Videos
[DFMO: an alternative therapeutic agent for human African trypanosomiasis]
J C Breton1, B Bouteille, T Sonan
1Institut de Neurologie tropicale, Faculté de Médecine de Limoges.
Bulletin De La Societe De Pathologie Exotique Et De Ses Filiales
|January 1, 1988
Summary
Alpha-difluoromethyl ornithine (DFMO) stops polyamine synthesis by inhibiting ornithine decarboxylase (ODC). This treatment eradicated Trypanosoma brucei brucei parasites in mice and is being developed for human use.
Area of Science:
- Biochemistry
- Parasitology
- Pharmacology
Context:
- Polyamines like putrescine and spermidine are crucial for cellular multiplication.
- Trypanosoma brucei brucei is a parasite that causes significant disease.
- Ornithine decarboxylase (ODC) is a key enzyme in polyamine biosynthesis.
Purpose:
- To investigate the efficacy of alpha-difluoromethyl ornithine (DFMO) as an inhibitor of ODC.
- To evaluate the therapeutic potential of DFMO against Trypanosoma brucei brucei infection.
Summary:
- DFMO irreversibly inhibits ODC, leading to reduced levels of essential polyamines.
- Administration of DFMO resulted in the complete eradication of Trypanosoma brucei brucei from the blood of infected mice.
- The mechanism involves disrupting polyamine synthesis, vital for parasite proliferation.
Impact:
- Demonstrates DFMO's potent antiparasitic activity against Trypanosoma brucei brucei.
- Highlights DFMO as a promising candidate for treating human infections caused by this parasite.
- Suggests a viable therapeutic strategy targeting polyamine metabolism in parasitic diseases.